Palladium-Mediated Bioorthogonal System for Prodrug Activation of N -Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors
Journal of Medicinal Chemistry · 14.11.2024 · 67 (21) · 19905-19924
DOI: 10.1021/acs.jmedchem.4c02419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 01.11.2024. Verfasst von Jinlong Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P.R. China. Hauptthemen laut MEDLINE: Prodrugs, Palladium, Tubulin Modulators, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: China Pharmaceutical University, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Bioorthogonal cleavage reactions have been developed as an intriguing strategy to enhance the safety of chemotherapeutics. Aiming to reduce the toxicity and improve the targeted release properties of the colchicine binding site inhibitors (CBSIs) based on previous work, a series of biologically inert prodrugs were further designed and synthesized through a bioorthogonal prodrug strategy. The therapeutic effects of prodrugs could be "turned-on" once combined with palladium resins. Particularly, prodrug 2b was 68.3-fold less cytotoxic compared to the parent compound, while its cytotoxicity was recovered in situ in the presence of palladium resins. Mechanism studies confirmed that 2b inhibited cell growth in the same manner as CBSIs. More importantly, in vivo efficacy studies demonstrated the efficient activation of 2b by palladium resins, resulting in significant inhibition of tumor growth (63.2%). These results suggest that prodrug 2b with improved safety and targeted release property catalyzed by a Pd-mediated bioorthogonal cleavage reaction deserves further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P.R. China.
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China.
- Division of Molecular Therapeutics & Formulation, School of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, U.K.
- Department of Hepatobiliary Surgery, The First People's Hospital of Kunshan, Suzhou 215132, P.R. China.
ORCID-Profile: Hong Yao, Jichao Chen, Jinyi Xu, Shengtao Xu
Förderung
- China Pharmaceutical University
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Li, J., Zhang, T., Wu, D., He, C., Weng, H., Zheng, T., Liu, J., Yao, H., Chen, J., Ren, Y., Zhu, Z., Xu, J., & Xu, S. (2024). Palladium-Mediated Bioorthogonal System for Prodrug Activation of N -Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors. Journal of Medicinal Chemistry, 67(21), 19905-19924. https://doi.org/10.1021/acs.jmedchem.4c02419
Vancouver
Li J, Zhang T, Wu D, He C, Weng H, Zheng T, et al. Palladium-Mediated Bioorthogonal System for Prodrug Activation of N -Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors. Journal of Medicinal Chemistry. 2024;67(21):19905-19924. doi:10.1021/acs.jmedchem.4c02419
BibTeX
@article{Li2024,
author = {Li, Jinlong and Zhang, Tong and Wu, Di and He, Chen and Weng, Haoxiang and Zheng, Tiandong and Liu, Jie and Yao, Hong and Chen, Jichao and Ren, Yansong and Zhu, Zheying and Xu, Jinyi and Xu, Shengtao},
title = {Palladium-Mediated Bioorthogonal System for Prodrug Activation of N -Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {21},
pages = {19905--19924},
doi = {10.1021/acs.jmedchem.4c02419}
}
EUVIMED